Real world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with HCV genotype 1 and 4.
Grazoprevir/elbasvir (GZR/EBR) was approved for the treatment of chronic hepatitis C virus (HCV) genotype (GT) 1 and 4 infected patients with or without compensated liver cirrhosis. The aim of this study was to assess GZR/EBR regimen in the real-world experience, particularly in previously "difficult-to-treat" patients with chronic kidney diseases, human immunodeficiency virus-coinfected, cirrhotics and treatment-experienced. The analysis included patients treated with GZR/EBR selected from 10152 individuals from the EpiTer-2 database, large national real-world study evaluating antiviral treatment in 22 Polish hepatology centres between 2015-2018. Data were completed retrospectively and submitted online. A total of 1615 patients who started GZR/EBR therapy in 2017 and 2018 with a female predominance (54%) and median age of 54 years were analysed. The majority were infected with GT1b (89%) and treatment-naïve (81%). Liver cirrhosis was diagnosed in 19% and 70% of patients had comorbidities, of which chronic renal disease was present in 7% and HIV-coinfection in 4%. Overall, a sustained virologic response (SVR) was achieved by 95% according to intent-to-treat (ITT) and 98% after exclusion of lost to follow-up (modified ITT). No differences were found in cure rate between all included patients and subpopulations previously considered as "difficult-to-treat". Majority of patients completed the treatment course as scheduled, adverse events (AEs) were mostly mild and did not lead to therapy discontinuation. GZR/EBR treatment carried-out in patients infected with HCV genotype 1 and 4 demonstrated good tolerability and an excellent SVR rate with no effectiveness reduction in so called "difficult-to-treat" populations.